

November 22, 2012

Interprotein Corporation

**Result of Assessment of Small molecule Protein-Protein Interaction
(PPI) inhibitors Designed by Interprotein Corporation**

Interprotein Corporation (President, Masato HOSODA; Headquarters: Osaka, Japan; hereinafter “Interprotein”) today announced the result of assessment of small molecule PPI inhibitors that were designed by INTENDD (Interprotein’s Engine for New Drug Design), a platform technology of Interprotein, under the collaborative research between Takeda Pharmaceutical Company Limited (Headquarters: Osaka, Japan; hereinafter “Takeda”) and Interprotein.

The compounds designed by Interprotein were assessed at Takeda for binding to the target protein at the molecular level, and approximately 11%*) of the compounds tested were confirmed to bind to the target protein. Takeda will proceed with further evaluation of the compounds based on the results.

*) It is generally recognized that hit rates of compounds against protein targets through computational drug design methods are well below 11%.

Contact:
Hirotugu KOMATSU, Ph.D.
Interprotein Corporation
TEL/FAX: +81-(0)42-770-9477
E-mail : info@interprotein.com